| RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity P Mandal, SB Berger, S Pillay, K Moriwaki, C Huang, H Guo, JD Lich, ... Molecular cell 56 (4), 481-495, 2014 | 569 | 2014 |
| An essential receptor for adeno-associated virus infection S Pillay, NL Meyer, AS Puschnik, O Davulcu, J Diep, Y Ishikawa, LT Jae, ... Nature 530 (7588), 108-112, 2016 | 502 | 2016 |
| AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR S Pillay, W Zou, F Cheng, AS Puschnik, NL Meyer, SS Ganaie, X Deng, ... Journal of Virology, JVI. 00391-17, 2017 | 187* | 2017 |
| Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification RM Deans, DW Morgens, A Ökesli, S Pillay, MA Horlbeck, M Kampmann, ... Nature chemical biology 12 (5), 361, 2016 | 175 | 2016 |
| An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor AM Dudek, S Pillay, AS Puschnik, CM Nagamine, F Cheng, J Qiu, ... Journal of virology 92 (7), e02213-17, 2018 | 120 | 2018 |
| Genome-Wide CRISPR/Cas9 Screening Identifies GPR108 as a Highly Conserved AAV Entry Factor AM Dudek, E Zinn, S Pillay, J Zengel, JE Carette, LH Vandenberghe MOLECULAR THERAPY 27 (4), 313-314, 2019 | 97* | 2019 |
| GPR108 is a highly conserved AAV entry factor AM Dudek, N Zabaleta, E Zinn, S Pillay, J Zengel, C Porter, ... Molecular Therapy 28 (2), 367-381, 2020 | 96 | 2020 |
| Host determinants of adeno-associated viral vector entry S Pillay, JE Carette Current Opinion in Virology 24, 124-131, 2017 | 95 | 2017 |
| Optimization of chimeric HIV‐1 virus‐like particle production in a baculovirus‐insect cell expression system S Pillay, A Meyers, AL Williamson, EP Rybicki Biotechnology progress 25 (4), 1153-1160, 2009 | 53 | 2009 |
| Cell-Selective Adeno-Associated Virus-Mediated SCN1A Gene Regulation Therapy Rescues Mortality and Seizure Phenotypes in a Dravet Syndrome Mouse … A Tanenhaus, T Stowe, A Young, J McLaughlin, R Aeran, IW Lin, J Li, ... Human Gene Therapy 33 (11-12), 579-597, 2022 | 40 | 2022 |
| Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles RJ Halsey, FL Tanzer, A Meyers, S Pillay, A Lynch, E Shephard, ... Virus research 133 (2), 259-268, 2008 | 31 | 2008 |
| Hunting Viral Receptors Using Haploid Cells S Pillay, JE Carette Annual Review of Virology 2, 219-239, 2015 | 23 | 2015 |
| HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice S Pillay, EG Shephard, AE Meyers, AL Williamson, EP Rybicki Journal of immune based therapies and vaccines 8 (1), 7, 2010 | 20 | 2010 |
| Methods and compositions for modulating aav infection S Pillay, J Carette, MS Chapman, N Meyer, A Puschnik, O Davulcu US Patent App. 15/774,223, 2018 | 12 | 2018 |
| Improved genome editing through inhibition of FANCM and members of the BTR dissolvase complex G de Alencastro, F Puzzo, M Pavel-Dinu, F Zhang, S Pillay, K Majzoub, ... Molecular Therapy 29 (3), 1016-1027, 2021 | 8 | 2021 |
| Hardwiring tissue-specific AAV transduction in mice through engineered receptor expression JR Zengel, YX Wang, J Wseo, JN Hamilton, B Wu, M Raie, C Holbrook, ... HUMAN GENE THERAPY 33 (23-24), A27-A27, 2022 | 3 | 2022 |
| An essential receptor for adeno-associated virus infection (vol 530, pg 108, 2016) S Pillay, NL Meyer, AS Puschnik, O Davulcu, J Diep, Y Ishikawa, LT Jae, ... NATURE 539 (7629), 456-456, 2016 | 3* | 2016 |
| Interactions of AAV-2 with Its Cellular Receptor, AAVR, Visualized by Cryo-Electron Microscopy NL Meyer, G Hu, Q Xie, O Davulcu, Y Ishikawa, A Noble, W Zou, F Cheng, ... MOLECULAR THERAPY 26 (5), 28-28, 2018 | 1 | 2018 |
| Cell-selective AAV-mediated SCN1A Gene Regulation Therapy Rescues Mortality and Seizure Phenotypes in a Dravet Syndrome Mouse Model and is Well … A Tanenhaus, T Stowe, A Young, J McLaughlin, R Aeran, W Lin, J Li, ... Human Gene Therapy, 2022 | | 2022 |
| Proteins Complex of the Fanconi Anemia Pathway as Determinant of AAV-Mediated Genomic Targeted Integration F Puzzo, G de Alencastro, M Pavel-Dinu, F Zhang, S Pillay, K Majzoub, ... MOLECULAR THERAPY 28 (4), 459-459, 2020 | | 2020 |
